ATP-TCA结合MDR水平检测在临床乳腺癌化疗药物筛选中的应用

目的建立乳腺癌个体化疗体系，减少滥用药物或过度用药给患者带来的副作用，提高化疗药物的有效率．方法分离、培养乳腺癌患者新鲜组织细胞，加入临床常用化疗药物，体外培养一定时间后，按ATP—TCA试剂盒说明书进行细胞ATP含量检测，根据荧光强度计算药物半数致死量及细胞生长增殖抑制率；提取切除的手术标本及癌旁组织RNA，RT—PCR，检测MDR基因表达水平；根据细胞敏感程度及MDR基因水平检测优化对患者的化疗方案．结果142例患者对常见的化疗药物敏感程度各有不同；在这些耐受病例中约有50％-80％病例MDR基因高表达．结论ATP—TCA配合MDR基因水平检测有利于建立个体化化疗体系，提高临床化疗药物的有效性．

Application of ATP-TCA in Combination with MDR Expression Detection in the Screening of Clinical Chemotherapeutic Drugs for Breast Cancer

Objective To establish an individual chemotherapy system for the treatment of breast cancer to reduce the adverse reactions induced by drug abuse or excessive medication and improve the therapeutic effect of chemotherapy drugs. Method Fresh tissue cells of breast cancer patients were separated and cultured, and then several commonly used ehemotherapeutics in clinic were added to the cells and incubate for a certain time. According to ATP-TCA kit instructions, ATP contents in the cells were detected. The median lethal dose and the cell growth and proliferation inhibition rates were calculated according to the fluorescence intensity. RNA in the removed surgical specimens and adjacent tissues was extracted and RT-PCR was used to detect MDR gene expression levels. Results The results of ATP-TCA detection showed that sensitivities of 142 patients to use chemotherapeutic drugs were different and those from MDR gene detection indicated that about 50% - 80% resistant cases presented high MDR gene expression. Conclusion ATP-TCA screening with MDR gene detection can help to establish the individual chemotherapy system and improve the effectiveness of chemotherapeutic drugs.